...
首页> 外文期刊>Journal of clinical apheresis. >Safety of donating multiple products in a single apheresis collection: Are we expecting too much?
【24h】

Safety of donating multiple products in a single apheresis collection: Are we expecting too much?

机译:在单个摘要集中捐赠多种产品的安全性:我们期待太多了吗?

获取原文
获取原文并翻译 | 示例

摘要

Modern blood separators rapidly process many liters of donor blood and efficiently collect vast quantities of blood components from donors, who may be stimulated with potent recombinant hematopoietic growth factors or cytokines. Accordingly, the potential risks of modern multiple product/unit apheresis donations and recombinant growth factors is analyzed in this report. As is true for all medical procedures, risks are associated with apheresis donations. Risks of a "standard" apheresis donation, in which one unit of PLTs or plasma is collected, are comparable to the risks of whole blood donation. Risks of multiple unit apheresis donations, in which either vast quantities of a single blood component or multiple units of various components are collected, are incompletely understood, particularly, when donors are stimulated with recombinant hematopoietic growth factors to increase component yields. To minimize donor risks and to increase knowledge of multiple component apheresis donations, both short-termproblems (e.g., donor reactions accompanying apheresis procedures and pre- vs. post-procedure changes in results of donor laboratory studies) and long-term problems (e.g., medical diagnoses/problems and abnormalities of donor blood counts and laboratory test results) should be monitored, ideally, by a repeat donor registry. When recombinant hematopoietic growth factors are prescribed, donors should give informed consent, and blood center professionals must be aware of 1) the effects of these drugs given at pharmacologic, rather than physiologic, doses; 2) the differences between the molecular structure of recombinant vs. natural/endogenous growth factors; 3) the fact that recombinant growth factors have both narrow/focused and broad biological activities; and 4) the probability that results of studies in sick/immunosuppressed patients may not be applicable to healthy/immunocompetent donors. J. Clin. Apheresis 18:135-140, 2003.
机译:现代血液分离器迅速加工许多升的供体血液,有效地从供体中收集大量的血液成分,他们可以用有效的重组造血生长因子或细胞因子刺激。因此,在本报告中分析了现代多产品/单位筛席捐赠和重组生长因子的潜在风险。对于所有医疗程序而言,风险与容纳剂捐赠有关。 “标准”容易内容捐赠的风险,其中收集了一个单位的PLTS或血浆,与全献献血的风险相媲美。多个单位容易内容施加的风险,其中收集了大量单个血液成分或各种组分的多个单元,特别是当供体用重组造血生长因子刺激以增加成分产率时。为了最大限度地减少捐助风险并增加短期问题的多组分血症捐赠的知识(例如,伴随患者的捐赠者反应和施用捐助者实验室研究结果的过程)和长期问题(例如,理想地,应由重复捐助者登记处监测供体诊断/问题和施用血液计数和实验室测试结果的异常。当规定重组造血生长因素时,捐助者应提供知情同意,血液中心专业人员必须了解1)这些药物在药物,而不是生理剂量的药物的影响; 2)重组与天然/内源性生长因子的分子结构之间的差异; 3)重组生长因素具有狭窄/聚焦和广泛的生物活性; 4)病人/免疫抑制患者的研究结果可能不适用于健康/免疫活性捐赠者的可能性。 J. Clin。阿草属18:135-140,2003。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号